Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria [Yahoo! Finance]
Disc Medicine, Inc. (IRON)
Company Research
Source: Yahoo! Finance
The study size was expanded to 183 participants due to patient and physician demand Results of the APOLLO study are expected in Q4 2026 WATERTOWN, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that the last participant has been randomized and dosed in the pivotal Phase 3 APOLLO trial of bitopertin in EPP. Originally planned as an N=150 study, the study was expanded to 183 participants due to patient and physician demand. “We are pleased to have completed enrollment in our APOLLO study in less than a year and we extend our gratitude to the EPP community for their continued contributions to the development of bitopertin,” said John Quisel, J.D., Ph.D., Chief Executive Officer and President of Disc. “The rapid enrollment of APOLLO underscores the urgent ne
Show less
Read more
Impact Snapshot
Event Time:
IRON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IRON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IRON alerts
High impacting Disc Medicine, Inc. news events
Weekly update
A roundup of the hottest topics
IRON
News
- IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your RightsGlobeNewswire
- Disc Medicine, Inc. Investigated by the Portnoy Law FirmGlobeNewswire
- Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic ProtoporphyriaGlobeNewswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc. - IRONPR Newswire
- IRON Investors Lose Up to $22/Share -- LEVI & KORSINSKY, LLP Investigates Disc MedicinePR Newswire
IRON
Earnings
- 2/26/26 - Miss
IRON
Sec Filings
- 3/4/26 - Form 4
- 3/2/26 - Form 144
- 2/27/26 - Form 4
- IRON's page on the SEC website